Details checkedClinical trial listing onlyCheckedregistry

Montelukast Hearing and Vestibular Study Cluster

Also known as: Montelukast, Montelukast for Meniere's disease, Montelukast for otitis media with effusion

Institution-led study cluster

Primary source

Sponsor / Institution

Institution-led study cluster

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 4

Status

Active

Target Gene

—

Route / Mode

Oral

Confidence

78%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States, Israel

Population

adult, pediatric, meniere-disease, study-cluster

Trial IDs

Mechanism

Two institution-led Phase 4 repurposing studies of oral montelukast: one active-not-recruiting trial for vertigo and hearing-loss outcomes in Meniere's disease, and one older registry-unknown trial in children with otitis media with effusion.

Indications

Hearing Loss Conductive Hearing Loss Meniere Disease Vestibular Disorders

Notes

ClinicalTrials.gov verifies two non-industry montelukast studies relevant to hearing or vestibular outcomes. The House Ear Institute/Cures Within Reach Meniere's disease trial is active, not recruiting; the Tel-Aviv pediatric OME registry row is historical with unknown status. This cluster is not evidence of a proprietary montelukast hearing-loss asset.

Evidence & Sources

2 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT04815187

Open

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT01967498

Open

Key Events

2013-07-01